31262-38-1

Basic information

• Product Name: propyl-delta(8)-tetrahydrocannabinol
• Synonyms: propyl-delta(8)-tetrahydrocannabinol
• CAS NO: 31262-38-1
• Molecular Formula: C19H26O2
• Molecular Weight: 286.40854
• Mol File: 31262-38-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 353.2°C at 760 mmHg
• Flash Point: 132.4°C
• Appearance: /
• Density: 1.034g/cm³
• Vapor Pressure: 1.79E-05mmHg at 25°C
• Refractive Index: 1.535
• CAS DataBase Reference: propyl-delta(8)-tetrahydrocannabinol(CAS DataBase Reference)
• NIST Chemistry Reference: propyl-delta(8)-tetrahydrocannabinol(31262-38-1)
• EPA Substance Registry System: propyl-delta(8)-tetrahydrocannabinol(31262-38-1)

Safety Data

• Hazardous Substances Data: 31262-38-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C19H26O2/c1-5-6-13-10-16(20)18-14-9-12(2)7-8-15(14)19(3,4)21-17(18)11-13/h7,10-11,14-15,20H,5-6,8-9H2,1-4H3/t14-,15-/m1/s1

Upstream product

• 20469-65-2 1-bromo-3,5-dimethoxybenzene 
• 500-49-2 5-propyl-1,3-benzenediol 
• 18881-04-4 (S)-cis-Verbenol 
• 62191-57-5 (6aR,10aR)-3-Bromo-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol 
• 106120-04-1 5-bromoresorcinol 
• 24274-48-4 cannabidivarin 
• 1132-21-4 3,5-dimethoxybenzoic acid 
• 41395-10-2 1,3-dimethoxy-5-propylbenzene 
• 41497-31-8 3,5-dimethoxyphenyl ethyl ketone 

Relevant articles and documents

Comparative topical anti-inflammatory activity of cannabinoids and cannabivarins

A selection of seven phytocannabinoids representative of the major structural types of classic cannabinoids and their corresponding cannabivarins was investigated for in vivo topical anti-inflammatory activity in the Croton oil mouse ear dermatitis assay. Differences in the terpenoid moiety were far more important for anti-inflammatory activity than those at the C-3 alkyl residue, suggesting the involvement not only of cannabinoid receptors, but also of other inflammatory end-points targeted by phytocannabinoids.

Synthesis and pharmacological evaluation of ether and related analogues of Δ8-, Δ9-, and Δ9,11-tetrahydrocannabinol

The primary goal of this research was to synthesize a series of ether analogues of the cannabinoid drug class and to evaluate their agonist and antagonist pharmacological properties in either the mouse or the rat. Agonist and antagonist activity was evaluated in mice using a multiple-evaluation procedure (locomotor activity, tail-flick latency, hypothermia, ring immobility) and activity in rats determined in a discriminative stimulus paradigm. Additionally, novel analogues were evaluated for their ability to bind to the THC receptor site labeled by 3H-CP-55,940. None of the cannabinoid analogues were capable of attenuating the effects of Δ9-THC (3 mg/kg) in either the rat (doses up to 10 mg/kg) or in the mouse (doses up to 30 mg/kg). It also appears that the compounds with minimal in vivo activity are not mixed agonist/antagonists. These data would suggest that the phenolic hydroxyl is important for receptor recognition (binding) and in vivo potency. Additionally, cannabinoid methyl ethers previously considered inactive have been found to produce limited activity. Lastly, data suggest that Δ9,11- THC is more potent than previous reports indicated, and does possess pharmacological activity.